logo

For the Inventor, By the Inventor

Barnet, United Kingdom

Joseph George Neduvelil

This inventor holds 5 USPTO granted patents. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Merck Frosst Canada & Co.. Active years: 1997-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joseph George Neduvelil. Retrieved from https://idiyas.com/inventor/joseph-george-neduvelil

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 80.0

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 18(Granted Patents)


Location History:

  • Barnet, GB (1997 - 2000)
  • London, GB (1999 - 2004)
  • East Barnet, GB (2008)

Company Filing History:

goldMedal4 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal1 out of 4,770 
 
Merck + Co., Inc.
 patents
bronzeMedal1 out of 80 
 
Merck Frosst Canada & Co.
 patents
where one patent can have more than one assignee

Years Active: 1997-2008

Loading Chart...
5 patents (USPTO):Explore Patents
1. 7365196 - Sulphonamido-substituted bridged bicycloalkyl derivatives (2008-04-29),
2. 6753410 - Investigational compounds (2004-06-22),
3. 6140347 - Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor (2000-10-31),
4. 5994374 - Substituted 1-indolylpropyl-4-benzyl-tetrahydropyridine derivatives (1999-11-30),
5. 5684006 - Isoxazole and pyrazole derivatives as dopamine receptor subtype ligands (1997-11-04),

Title: Joseph George Neduvelil: Innovator in Alzheimer's Disease Treatment

Introduction

Joseph George Neduvelil is a notable inventor based in Barnet, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating Alzheimer's disease. With a total of 5 patents to his name, Neduvelil's work has garnered attention for its potential impact on healthcare.

Latest Patents

Neduvelil's latest patents include innovative compounds such as sulphonamido-substituted bridged bicycloalkyl derivatives. These compounds are designed to inhibit gamma-secretase, making them useful in the treatment and prevention of Alzheimer's disease. Another significant invention involves investigational compounds that also act as inhibitors of gamma-secretase, targeting diseases associated with the beta-amyloid peptide, including Alzheimer's disease.

Career Highlights

Throughout his career, Joseph George Neduvelil has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corp. and Merck Frosst Canada & Co. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Neduvelil has collaborated with esteemed colleagues such as Graham A Showell and Andrew Madin. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality and impact of his inventions.

Conclusion

Joseph George Neduvelil's contributions to the field of pharmaceuticals, particularly in the context of Alzheimer's disease, highlight his role as an influential inventor. His innovative patents and collaborations reflect a commitment to improving healthcare outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…